Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574964 · ClinicalTrials.gov registry record · Phase 2
Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme
A Phase 2 study, sponsored by University of Iowa.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00574964 is a Phase 2 study that was terminated before completion, run by University of Iowa. The registered enrollment target is 50 participants.
The verdict
NCT00574964, a Phase 2 study, was terminated before completion, sponsored by University of Iowa.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if combining all three treatments of Gliadel wafers, Temozolomide and Radiation therapy at the same time is safe and more effective than one treatment at a time. The study will measure the survival of subjects treated with this combination of drugs.
Interventions
- OTHER Gliadel Wafer, Temodar and Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574964
The ClinicalTrials.gov registry entry for NCT00574964 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gliadel Wafer, Temodar and Radiotherapy is the first listed.
NCT00574964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574964 about?
NCT00574964 is a clinical study titled "Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme". The purpose of this research study is to determine if combining all three treatments of Gliadel wafers, Temozolomide and Radiation therapy at the same time is safe and more effective than one treatment at a time. The study will measure the survival of subjects treated with this combination of drugs.
What is the current status of trial NCT00574964?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00574964?
The interventions under investigation include: Gliadel Wafer, Temodar and Radiotherapy (OTHER).
Who is sponsoring clinical trial NCT00574964?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.